Dynavax to Webcast Presentation at UBS Global Life Sciences Conference on Thursday, September 30, 2004
BERKELEY, Calif., Sept. 27 /PRNewswire-FirstCall/ -- Dynavax Technologies (Nasdaq: DVAX) announced today that Dino Dina, M.D., President and CEO, will present an overview of the company at the UBS Warburg Global Life Sciences Conference in New York City.
Dr. Dina's presentation will be webcast live beginning at or about 11:30 a.m. eastern time on Thursday, September 30, 2004. The webcast presentation may be accessed by visiting http://event.streamx.us/event/default.asp?event=ubs20040927 , where it will be archived for 30 days following the presentation.
About Dynavax
Dynavax Technologies Corporation discovers, develops, and intends to commercialize innovative products to treat and prevent allergies, infectious diseases, and chronic inflammatory diseases using versatile, proprietary approaches that alter immune system responses in highly specific ways. Our clinical development programs are based on immunostimulatory sequences, or ISS, which are short DNA sequences that enhance the ability of the immune system to fight disease and control chronic inflammation. ISS are being developed in three separate indications: a ragweed allergy program and a Hepatitis B vaccine program in late stage clinical development, and an asthma program that just completed a Phase II exploratory trial.
SOURCE Dynavax Technologies Corporation
09/27/2004
CONTACT: Jane Green, Vice President, Corporate Communications, of
Dynavax Technologies Corporation, 510-665-4630, or jgreen@dvax.com
Web site: http://www.dynavax.com
(DVAX)
09/27/2004 20:10 EDT http://www.prnewswire.com